Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Giovanna Scarfone"'
Autor:
Massimo Candiani, Alice Bergamini, Francesco Raspagliesi, Floriana Mascilini, Enrico Breda, Gabriella Ferrandina, Giorgio Giorda, Antonella Savarese, Giovanna Scarfone, Luca Bocciolone, Saverio Tateo, U. De Giorgi, Domenica Lorusso, Gennaro Cormio, G. Mangili, Anila Kardhashi, Anna Myriam Perrone, Nicoletta Biglia, Chiara Cassani, Salvatore Antonio Pignata
Publikováno v:
Gynecologic oncology. 154(2)
Objective: About 30% of Adult type granulosa cell tumors of the ovary (AGCTs) are diagnosed in fertile age. In stage I, conservative surgery (fertility-sparing surgery, FSS), either unilateral salpingo-oophorectomy (USO) or cystectomy are possible op
Autor:
Jessica Ottolina, Sabrina Chiara Cecere, Claudia Marchetti, Giovanna Scarfone, A Gadducci, Gabriella Ferrandina, Massimo Candiani, Giorgio Giorda, D. A Pellegrini, L. Frigerio, Vera Loizzi, Gennaro Cormio, P. De Iaco, G. Mangili
Publikováno v:
Gynecologic oncology. 143(2)
OBJECTIVE: Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemoth
Autor:
Sonia Cipriani, Massimo Candiani, Alice Bergamini, Gianluca Taccagni, A. Villa, Paola Viganò, Giovanna Scarfone, Fabio Parazzini, Giorgia Mangili, Stefania Noli
Publikováno v:
Gynecologic oncology. 133(3)
Objective Endometrioid and clear cell ovarian tumors have been referred to as "endometriosis associated ovarian cancers". However, very few studies have compared clinical and prognostic features of endometriosis-associated cancers or cancers not asso
Publikováno v:
Gynecologic Oncology. 81:331-333
Publikováno v:
Gynecologic Oncology. 43:24-28
From December 1986 to April 1990, 40 consecutive ovarian cancer patients who relapsed after response to cisplatin-based chemotherapy regimens were treated with seven courses of weekly cisplatin, in combination with epirubicin or etoposide. The overal
Autor:
Sonia Cipriani, Giovanna Stellato, Fabio Parazzini, Giorgio Bolis, Gianpiero Polverino, Giovanna Scarfone
Publikováno v:
Gynecologic oncology. 99(2)
We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules.This analysis included
Autor:
Fabio Parazzini, Giorgio Bolis, Cesarina Sciatta, Giovanna Scarfone, P. Guarnerio, Cristina Rosa, Gian Piero Polverino
Publikováno v:
Gynecologic oncology. 83(3)
Objective. The purpose of this study was to define the maximum tolerated dose (MTD) of topotecan given as escalating doses combined to a fixed dosage of carboplatin in late relapsing ovarian carcinomas. Methods. Women with relapsing ovarian cancer mo
Autor:
Francesca Chiaffarino, Giovanna Scarfone, Eva Negri, Fabio Parazzini, Guido Benzi, Silvia Franceschi, Carlo La Vecchia
Publikováno v:
Gynecologic oncology. 81(2)
Objectives. While parity is a protective factor in ovarian cancer, the role of time factors of pregnancy and birth is still controversial. We considered therefore the role of birth timing in the risk in ovarian cancer from a large case-control study.
Autor:
Massimo Franchi, Giorgia Mangili, Mauro Melpignano, Giorgio Giardina, Saverio Tateo, Giovanna Scarfone, Giorgio Bolis, A. Villa, Fabio Parazzini, M. Presti
Publikováno v:
Gynecologic oncology. 81(1)
Objective. The aim of the study was to analyze the benefit/toxicity profile of a second-line treatment with carboplatin alone or carboplatin plus another non-cross-resistant drug (epidoxorubicin) in ovarian cancer patients sensitive to cisplatin-base
Publikováno v:
Gynecologic oncology. 80(1)
The objective of this open uncontrolled study was to evaluate the toxicity and efficacy of topotecan in ovarian cancer cases with microscopic small residual disease to a first-line treatment, given as sequential treatment, including carboplatinum and